Skip to content

Awarded to RADHA PHARMACEUTICALS INC on October 6, 2022

This is an award notice, not an open solicitation. Related open opportunities are listed below.

Bupropion HCL ER

DEPT OF DEFENSE

Notice type
Award Notice
Solicitation #
SPE2D2-23-D-0002
NAICS
325412
PSC
6505
Posted
September 14, 2026
Response due
—
Place of performance
Hauppauge, NY

Description

Modification P00010 SPE2D223D0002 is issued to invoke option year 4 for Bupropion HCL ER National Contract. Modification P00009 SPE2D223D0002 is issued to incorporate clause 52.222-90, Addressing DEI Discrimination by Federal Contractors (DEVIATION 2026-O0040, REVISION 1) (APR 2026). Modification P00008 SPE2D223D0002 is issued to invoke option year 3 for Bupropion HCL ER National Contract. Modification P00007 SPE2D223D0002 is issued in accordance with DoD Class Deviation 2025-O0003 and Class Deviation 2025-O0004 into subject solicitation. Modification P00006 SPE2D223D0002 is issued to invoke option year 2 for Bupropion HCL ER National Contract. Modification P00005 SPE2D223D0002 is issued to incorporate FAR 52.204-30 Federal Acquisition Supply Chain Security Act Orders into subject solicitation. NATIONAL CONTRACT SPE2D2-23-D-0002 BUPROPION HCL ER

Source: SAM.gov, as posted. Verify the current solicitation before responding.

Get alerts when DEPT OF DEFENSE posts the next one

Mindy watches SAM.gov every day and emails you new notices that match what you sell — like NAICS 325412. Free daily alerts.

View the original notice on SAM.gov ↗

Open opportunities in NAICS 325412